Design in nonlinear mixed effects models: Optimization using the Fedorov–Wynn algorithm and power of the Wald test for binary covariates
暂无分享,去创建一个
France Mentré | Sylvie Retout | Emmanuelle Comets | Adeline Samson | A. Samson | F. Mentré | E. Comets | S. Retout
[1] Jerry R. Nedelman,et al. On some “disadvantages” of the population approach , 2005, The AAPS Journal.
[2] France Mentré,et al. Extension of the SAEM algorithm to left-censored data in nonlinear mixed-effects model: Application to HIV dynamics model , 2006, Comput. Stat. Data Anal..
[3] Mats O. Karlsson,et al. Comparison of some practical sampling strategies for population pharmacokinetic studies , 1996, Journal of Pharmacokinetics and Biopharmaceutics.
[4] Dongwoo Kang,et al. Sample Size Computations for PK/PD Population Models , 2005, Journal of Pharmacokinetics and Pharmacodynamics.
[5] Goonaseelan Pillai,et al. Non-Linear Mixed Effects Modeling – From Methodology and Software Development to Driving Implementation in Drug Development Science , 2005, Journal of Pharmacokinetics and Pharmacodynamics.
[6] Hulin Wu,et al. Modeling Long-Term HIV Dynamics and Antiretroviral Response: Effects of Drug Potency, Pharmacokinetics, Adherence, and Drug Resistance , 2005, Journal of acquired immune deficiency syndromes.
[7] Marc Lavielle,et al. Maximum likelihood estimation in nonlinear mixed effects models , 2005, Comput. Stat. Data Anal..
[8] Hulin Wu,et al. Statistical methods for HIV dynamic studies in AIDS clinical trials , 2005, Statistical methods in medical research.
[9] Brian Whiting,et al. Experimental design and efficient parameter estimation in population pharmacokinetics , 1990, Journal of Pharmacokinetics and Biopharmaceutics.
[10] Dongwoo Kang,et al. A sample size computation method for non‐linear mixed effects models with applications to pharmacokinetics models , 2004, Statistics in medicine.
[11] France Mentré,et al. Optimization of Individual and Population Designs Using Splus , 2003, Journal of Pharmacokinetics and Pharmacodynamics.
[12] Stephen B. Duffull,et al. Prospective Evaluation of a D-Optimal Designed Population Pharmacokinetic Study , 2003, Journal of Pharmacokinetics and Pharmacodynamics.
[13] France Mentré,et al. Population Pharmacokinetic Analysis and Optimization of the Experimental Design for Mizolastine Solution in Children , 2001, Journal of Pharmacokinetics and Pharmacodynamics.
[14] Kathryn Chaloner,et al. D- and c-optimal designs for exponential regression models used in viral dynamics and other applications , 2003 .
[15] France Mentré,et al. Further Developments of the Fisher Information Matrix in Nonlinear Mixed Effects Models with Evaluation in Population Pharmacokinetics , 2003, Journal of biopharmaceutical statistics.
[16] France Mentré,et al. Fisher information matrix for non‐linear mixed‐effects models: evaluation and application for optimal design of enoxaparin population pharmacokinetics , 2002, Statistics in medicine.
[17] Stephen B. Duffull,et al. The use of simulated annealing for finding optimal population designs , 2002, Comput. Methods Programs Biomed..
[18] Hulin Wu,et al. Design of viral dynamic studies for efficiently assessing potency of anti-HIV therapies in AIDS Clinical Trials , 2002 .
[19] V. Carey,et al. Mixed-Effects Models in S and S-Plus , 2001 .
[20] A. Ding,et al. Assessing antiviral potency of anti-HIV therapies in vivo by comparing viral decay rates in viral dynamic models. , 2001, Biostatistics.
[21] H Wu,et al. Population HIV‐1 Dynamics In Vivo: Applicable Models and Inferential Tools for Virological Data from AIDS Clinical Trials , 1999, Biometrics.
[22] I. Marschner. Design of HIV viral dynamics studies. , 1998, Statistics in medicine.
[23] V De Gruttola,et al. Estimation of HIV dynamic parameters. , 1998, Statistics in medicine.
[24] Alan S. Perelson,et al. Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy , 1998 .
[25] A S Perelson,et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. , 1998, Science.
[26] Alain Mallet,et al. Optimal design in random-effects regression models , 1997 .
[27] Eric Walter,et al. Identification of Parametric Models: from Experimental Data , 1997 .
[28] D. Bates,et al. Approximations to the Log-Likelihood Function in the Nonlinear Mixed-Effects Model , 1995 .
[29] W. Näther. Optimum experimental designs , 1994 .
[30] P. Laycock,et al. Optimum Experimental Designs , 1995 .
[31] D. Bates,et al. Nonlinear mixed effects models for repeated measures data. , 1990, Biometrics.
[32] A. Mallet. A maximum likelihood estimation method for random coefficient regression models , 1986 .
[33] T. Louis. Finding the Observed Information Matrix When Using the EM Algorithm , 1982 .
[34] W. J. Studden,et al. Theory Of Optimal Experiments , 1972 .
[35] L. Sheiner,et al. Modelling of individual pharmacokinetics for computer-aided drug dosage. , 1972, Computers and biomedical research, an international journal.
[36] F J Lewis,et al. Continuous patient monitoring with a small digital computer. , 1972, Computers and biomedical research, an international journal.
[37] H. Wynn. Results in the Theory and Construction of D‐Optimum Experimental Designs , 1972 .
[38] J. Kiefer,et al. Optimum Designs in Regression Problems , 1959 .